Author(s)

Dongxu Ao^1*, Meng Wang¹, Jinyuan Xie², Yang Zhang¹, Xinran Zhang¹, Ya Shu¹, Chenshi Lin¹, Qingqing Ye^3#

¹Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
²Department of Joint Surgery and Sports Medicine, Jingmen Central Hospital, Jingmen, China.
³Department of Breast Surgery, The First Affiliated Hospital of Yangtze University, Jingzhou, China.

Objective: To evaluate the efficacy and safety of EGFR-TKI with the radiotherapy in EGFR mutant metastatic NSCLC. Methods: Retrospective analysis of 72 patients with stage IV lung cancer with EGFR-sensitive mutation. Patients in the A group were treated with the first-generation EGFR-TKI (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor) combined with radiotherapy for primary tumors (34 cases). The B group was treated with the first-generation EGFR-TKI alone until the disease progressed (38 cases). PFS, OS, pulmonary infection and hematological toxicity during treatment were commented in both groups. Results: The objective remission rate was 47.1% (16/34) in the A group and 21.1% (8/38) in the B group. There was a significant difference between the two groups. There was no significant difference in hematological toxicity between the A group and the B group. There were 10 patients (29.4%) with degree II pulmonary infection in the A group and 3 patients (7.9%) in the B group. The difference between the two groups was statistically significant, suggesting that the incidence of pneumonia in the A group was higher than that in the B group. The median PFS (Progression-Free Survival)) and OS (Overall Survival) of the A group were significantly longer than those of the B group (16.5 months vs 9 months) and the median OS (36 months vs 19 months). The PFS and OS in the A group were significantly longer than those in the B group. Conclusion: EGFR-TKI combined with primary radiotherapy can significantly prolong the drug resistance time of EGFR mutant metastatic NSCLC.

Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, Radiotherapy

Ao, D. , Wang, M. , Xie, J. , Zhang, Y. , Zhang, X. , Shu, Y. , Lin, C. and Ye, Q. (2024) Efficacy and Safety of Primary Radiotherapy in Combination with EGFR-TKIs for Non-Small Cell Lung Cancer Harboring EGFR Mutation. Journal of Biosciences and Medicines, 12, 142-154. doi: 10.4236/jbm.2024.129014.